ECOR (electroCore) LT-Debt-to-Total-Asset : 0.18 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is electroCore LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. electroCore's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.18.

electroCore's long-term debt to total assets ratio increased from Dec. 2023 (0.03) to Dec. 2024 (0.18). It may suggest that electroCore is progressively becoming more dependent on debt to grow their business.

electroCore LT-Debt-to-Total-Asset Historical Data

The historical data trend for electroCore's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

electroCore LT-Debt-to-Total-Asset Chart

electroCore Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.02

0.03

0.18

electroCore Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.11	0.16	0.18	0.18

electroCore LT-Debt-to-Total-Asset Calculation

electroCore's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	3.775	/	20.471
	=	0.18

electroCore's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	3.775	/	20.471
	=	0.18

electroCore (NAS:ECOR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

electroCore LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of electroCore's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

electroCore Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » electroCore Inc (NAS:ECOR) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Forge Way, Suite 205, Rockaway, NJ, USA, 07866

Website

https://www.electrocore.com

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

Executives

Daniel S Goldberger	director, officer: Chief Executive Officer	24 CARPENTER ROAD, CHESTER NY 10918
Thomas J. Errico	director, 10 percent owner	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 97920
John P Gandolfo	director	62 TERRACE ROAD, WAYNE NJ 07470
Joseph P Errico	director, 10 percent owner, officer: See Remarks	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Trevor J Moody	director	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Julie Ann Goldstein	director	205 FORGE WAY, ROCKAWAY NJ 07866
Patricia Wilber	director	205 FORGE WAY, SUITE 205, ROCKAWAY NJ 07866
Brian M Posner	officer: Chief Financial Officer	1590 REED ROAD, PENNINGTON NJ 08534
Tullis James L L	director	100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Thomas M Patton	director	C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
F Peter Cuneo	director	10 EAST 40TH ST, NEW YORK NY 10016
Stephen Ondra	director	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Nicholas Colucci	director	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Michael G Atieh	director	MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
Carrie Smith Cox	director	SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033